{
    "clinical_study": {
        "@rank": "35280", 
        "arm_group": {
            "arm_group_label": "L19TNF\u03b1 + doxorubicin", 
            "arm_group_type": "Experimental", 
            "description": "Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNF\u03b1 in combination with 60 mg/m2 of doxorubicin."
        }, 
        "brief_summary": {
            "textblock": "Phase Ib study of the tumor-targeting human L19TNF\u03b1 monoclonal antibody-cytokine fusion\n      protein in combination with doxorubicin in patients with advanced solid tumors.\n\n      This study foresees the recruitment of up to 28 patients with advanced solid tumors who in\n      the opinion of the Principal Investigator are deemed suitable for combination therapy of\n      L19TNF\u03b1 and doxorubicin."
        }, 
        "brief_title": "L19TNF\u03b1 in Combination With Doxorubicin in Patients With Advanced Solid Tumours", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Advanced Tumors Amenable to Anthracycline Therapy", 
            "Breast Cancer Amenable to Anthracycline Therapy"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "L19TNF is a recombinant fusion protein composed of a fully human recombinant monoclonal\n      antibody (L19) and the human tumor necrosis factor-alpha, a primary mediator of immune\n      regulation and inflammation.\n\n      As an anti-tumor agent, TNF exerts its major effects via a preferential toxicity for the\n      endothelial cells of the tumor-associated vasculature and an increase of the antitumor\n      immune response. Given at sufficient doses (e.g. intratumorally or in the ILP setting with\n      melphalan), TNF causes significant tumor shrinkage in solid cancer subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically or cytologically confirmed advanced solid cancer deemed\n             suitable for combination therapy of L19TNFalfa and doxorubicin.\n\n          -  For breast cancer patients only:\n\n          -  Patients not suitable for trastuzumab therapy (i.e., no evidence of\n             HER2-overexpressing disease, or trastuzumab therapy exhausted in HER2-overexpressing\n             disease).\n\n          -  Patients not suitable for lapatinib plus capecitabine therapy in HER2-overexpressing\n             disease.\n\n          -  Patients not suitable for lapatinib plus letrozolo therapy in HER2-overexpressing\n             disease and HR + disease.\n\n          -  Patients aged >/= 18 years old with advanced or metastatic solid tumor in whom\n             standard anticancer therapies have been exhausted, or who are amenable for a\n             doxorubicin monotherapy according to the discretion of the Principal Investigators\n             and previously treated with a cumulative dose of anthracyclines (</= 300 mg/mq), or\n             chemotherapy- naive.\n\n          -  Eastern cooperative oncology group (ECOG) performance status </= 2.\n\n          -  Patients may have received previous chemotherapy (>/=4 weeks prior therapy) or\n             radiation therapy (>/=6 weeks prior therapy), but they must be amenable for\n             doxorubicin treatment according to the discretion of the Principal Investigator.\n\n          -  Patients must have at least one unidimensionally measurable lesion by computed\n             tomography as defined by criteria version 1.1. This lesion must not have been\n             irradiated during previous treatments.\n\n          -  Previous anthracycline therapy, including liposomal doxorubicin, for metastatic\n             and/or adjuvant disease is allowed. However, patients must not have received a\n             cumulative anthracycline dose of more than 300 mg/mq of doxorubicin, nor more than\n             500 mg/mq of epirubicin, nor more than 600 mg/mq of pegylated or non-pegylated\n             liposomal doxorubicin prior to study entry, in order to avoid\n             anthracycline-associated cardiotoxicity.\n\n          -  Life expectancy more than 3 months.\n\n          -  Absolute neutrophil count (ANC) </= 1.5 x 10^9/L, platelets </= 100 x 10^9/L and\n             haemoglobin (Hb) </= 9.5 g/dl.\n\n          -  All acute adverse effects (excluding alopecia) of any prior therapy (including\n             surgery, radiation therapy, chemotherapy) must have resolved to </= Grade 1, except\n             elevated liver transaminases judged to be associated with tumor infiltration (see\n             below) (graded according to the National Cancer Institute CTCAE v.4.02 dated\n             September 15, 2009).\n\n          -  Alkaline phosphatase (AP), alanine aminotransferase (ALT) and/or aspartate\n             aminotransferase (AST) </= 2.5 x upper limit of normal (ULN), and total bilirubin </=\n             2.0 mg/gL, unless liver involvement by the tumor, in which case the transaminase\n             levels up to 5 x ULN are allowed.\n\n          -  Creatinine </= 1.5 ULN or 24 h creatinine clearance </= 60 mL/min.\n\n          -  Testing negative for acute or chronic infection with hepatitis B or C virus, or human\n             immunodeficiency virus 1 or 2.\n\n          -  Negative pregnancy test for females of childbearing potential at the screening visit.\n\n          -  Commitment from patient to practice medically appropriate/acceptable method of birth\n             control beginning 30 days before study entry and continuing until 3 months following\n             the last treatment with study drug. Excluding women without childbearing potential;\n             menopause at least 2 years earlier, tubal ligation at least 1 year earlier, or total\n             hysterectomy. The definition of effective contraception will be based on the\n             guidelines ICH M3 rev2.\n\n          -  Evidence of a personally signed and dated EC-approved ICF indicating that the patient\n             (or legally acceptable representative) has been informed of all pertinent aspects of\n             the study.\n\n          -  Willingness and ability to comply with the scheduled visits, treatment plan,\n             laboratory tests and other study procedures.\n\n        ICF must be obtained for all the patients before enrollment into the study.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breast-feeding. Patients must agree to use effective contraception, or\n             be surgically sterile or postmenopausal. The definition of effective contraception\n             will be based on the guidelines ICH M3 rev2.\n\n          -  Presence of active infections (e.g. requiring antimicrobial therapy) or other severe\n             concurrent disease, which, in the opinion of the investigator, would place the\n             subject at undue risk or interfere with the study.\n\n          -  Presence of known brain metastases. If patient is symptomatic, negative CT scan\n             within two months before study beginning is required. However, presence of controlled\n             brain metastases (i.e., evaluated as SD of PR after radiotherapy) is allowed.\n\n          -  Known cancer of other primary origin within the prior 5 years.\n\n          -  History of chronic hepatitis B or C, or chronic active hepatitis or active autoimmune\n             diseases.\n\n          -  Cardiac disease as manifested by any of the following:\n\n          -  > Grade II heart failure, graded per New York Heart Association (NYHA) criteria.\n\n          -  History within the last year of acute or subacute coronary syndromes including\n             myocardial infarction, unstable or severe stable angina pectoris.\n\n          -  Irreversible cardiac arrhythmias requiring permanent medication.\n\n          -  Ejection fraction less than the institutional lower limit of normal as assessed by\n             MUGA scan or echocardiogram.\n\n          -  Uncontrolled hypertension.\n\n          -  Ischemic peripheral vascular disease (Grade IIb-IV).\n\n          -  Severe rheumatoid arthritis.\n\n          -  Severe diabetic retinopathy.\n\n          -  History of allograft or stem cell transplantation.\n\n          -  Major surgery or trauma within 4 weeks prior to start of study treatment.\n\n          -  Known history of allergy to TNFalfa, Anthracyclines or other intravenously\n             administered human proteins/peptides/antibodies.\n\n          -  Chemotherapy (standard or experimental), or therapy with an investigational agent\n             within 4 weeks prior to start of study treatment, and radiation within 6 weeks prior\n             therapy.\n\n          -  Cumulative exposure to anthracycline-containing chemotherapy (patients received a\n             cumulative anthracycline dose of more than 300 mg/mq of doxorubicin or of more than\n             500 mg/mq of epirubicin or pegylated or non-pegylated liposomal doxorubicin), prior\n             to study entry precluding the application of at least an additional 150 mg/mq\n             doxorubicin (total dose for 2 cycles of study therapy).\n\n          -  Treatment with an investigational study drug within six weeks before beginning of\n             treatment with L19TNFalfa.\n\n          -  Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6\n             weeks before administration of study treatment.\n\n          -  Growth factors or immunomodulatory agents within 7 days prior to the administration\n             of study treatment.\n\n          -  Neuropathy > Grade 1.\n\n          -  Patient requires or is taking corticosteroids or other immunosuppressant drugs on a\n             long-term basis. Limited use of corticosteroids to treat or prevent acute\n             hypersensitivity reactions is not considered an exclusion criterion.\n\n          -  Concurrent therapy with warfarin at doses greater than 1 mg/day or equivalent doses\n             of other coumarin derivatives.\n\n          -  Participation in another interventional clinical trial during participation in this\n             trial.\n\n          -  Expectation that the patient will not be able to complete at least 6 weeks of\n             therapy.\n\n          -  Any conditions that in the opinion of the investigator could hamper compliance with\n             the study protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076620", 
            "org_study_id": "PH-L19TNFDOXO-01/12", 
            "secondary_id": "2012-000950-75"
        }, 
        "intervention": {
            "arm_group_label": "L19TNF\u03b1 + doxorubicin", 
            "description": "Intravenous (i.v.) infusions of L19TNF\u03b1 (from 10.4, 13 and 17\u03bcg/kg) on days 1, 3, and 5 over 120 minutes via automated device (perfusor).\nDoxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNF\u03b1 administration.\nStudy design:\nCohort 1 --> 10.4 \u03bcg/kg L19TNF\u03b1 + Doxorubicin (fixed dose) Cohort 2 --> 13 \u03bcg/kg L19TNF\u03b1 + Doxorubicin (fixed dose) Cohort 3 --> 17 \u03bcg/kg L19TNF\u03b1 + Doxorubicin (fixed dose)\nPatients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 22. Patients will receive additional cycles of combination therapy for a maximum of 4.5 months, or exhaustion of cumulative doxorubicin dose (360 or 550mg/m2) until disease progression, unacceptable toxicity,  withdrawal of consent or at the discretion of the treating physician, whichever occurs first.", 
            "intervention_name": "Drug: L19TNF\u03b1 in combination with doxorubicin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "L19", 
            "monoclonal", 
            "antibody", 
            "doxorubicin", 
            "TNF\u03b1", 
            "solid tumour", 
            "breast cancer", 
            "anthracycline"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Christoph Schliemann, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4tsklinikum M\u00fcnster"
                }, 
                "investigator": {
                    "last_name": "Christoph Schliemann, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Filippo De Braud, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }, 
                    "name": "Fondazione IRCCS Istituto Nazionale dei Tumori"
                }, 
                "investigator": {
                    "last_name": "Filippo De Braud, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of the Tumor-targeting Human L19TNF\u03b1 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours", 
        "overall_contact": {
            "email": "regulatory@philogen.com", 
            "last_name": "Leonardo Giovannoni, Dr", 
            "phone": "(0039) 0577 17816"
        }, 
        "overall_official": [
            {
                "affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori", 
                "last_name": "Filippo De Braud, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum M\u00fcnster", 
                "last_name": "Christoph Schliemann, Dr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: National Institute of Health", 
                "Italy: Ethics Committee", 
                "Germany: Paul-Ehrlich-Institut", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Establish the MTD and the RD of L19TNF\u03b1 when administered in combination with doxorubicin.", 
                "measure": "Maximum tolerated dose (MTD) and recommended dose (RD)", 
                "safety_issue": "Yes", 
                "time_frame": "29 days"
            }, 
            {
                "description": "To investigate the safety, tolerability of L19TNF\u03b1 and doxorubicin when given as a combination", 
                "measure": "Safety and tolerability of L19TNF\u03b1 in combination with doxorubicin", 
                "safety_issue": "Yes", 
                "time_frame": "29 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Investigate the pharmacokinetics of L19TNF\u03b1", 
                "measure": "Pharmacokinetics of L19TNF\u03b1", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Investigate the potential induction of human anti-fusion protein antibodies (HAFA) through standard laboratory analysis.", 
                "measure": "Human anti-fusion protein antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "max. 12 months"
            }, 
            {
                "description": "To investigate the antitumor activity in terms of objective response rate (ORR), progression -free survival (PFS) rate and median overall survival (mOS) of L19TNF\u03b1 when administered in combination with a fixed dose of doxorubicin", 
                "measure": "Treatment efficacy (ORR, PFS, mOS)", 
                "safety_issue": "No", 
                "time_frame": "max. 12 months"
            }
        ], 
        "source": "Philogen S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philogen S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}